EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia

Anne Marie Morse, Yves Dauvilliers, Isabelle Arnulf, Michael J Thorpy, Nancy Foldvary-Schaefer, Patricia Chandler, Abby Chen, Luke Hickey, Jed Black, Richard K Bogan

Journal of Clinical Sleep Medicine · 2023

DOI: 10.5664/jcsm.10698 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Sleep Medicine, 2023. Verfasst von Anne Marie Morse und 9 weiteren Autor:innen. Beteiligte Einrichtung: Janet Weis Children's Hospital, Geisinger, Danville, Pennsylvania. Hauptthemen laut MEDLINE: Sodium Oxybate, Idiopathic Hypersomnia, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY OBJECTIVES: To evaluate 6-month efficacy and safety of low-sodium oxybate in people with idiopathic hypersomnia during an open-label extension period (OLE) of a phase 3 clinical trial. METHODS: Efficacy measures included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Patient Global Impression of Change (PGIc), Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). Treatment-emergent adverse events were collected throughout the OLE. RESULTS: The OLE population included 106 participants. Most were female (71%) and White (83%), and the mean (SD) age was 41.0 (13.8) years. ESS scores decreased (improved) during the OLE (mean [SD], study baseline: 16.3 [2.8]; OLE week 2: 6.7 [4.7]; OLE end: 5.3 [3.7]), and IHSS total scores trended toward a decrease (study baseline: 32.6 [7.3]; OLE week 2: 16.2 [8.9]; OLE end: 14.8 [8.6]. Median (minimum, maximum) paired differences from OLE week 2 to OLE end were ESS, -1.0 (-20, 7; nominal P = .012); IHSS, -1.0 (-31, 19; nominal P = .086). The proportion of participants reporting PGIc ratings of "very much improved" increased from 36.7% at OLE week 2 to 53.8% at the OLE end. The FOSQ-10 and WPAI:SHP scores remained stable during OLE. The incidence of newly reported treatment-emergent adverse events decreased over the duration of the OLE. CONCLUSIONS: Efficacy and safety of low-sodium oxybate were maintained or improved during the 6-month OLE, supporting long-term treatment with low-sodium oxybate in adults with idiopathic hypersomnia. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension; URL: https://clinicaltrials.gov/study/NCT03533114; Identifier: NCT03533114 and Registry: EU Clinical Trials; Name: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension; URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001311-79/results; Identifier: 2018-001311-79. CITATION: Morse AM, Dauvilliers Y, Arnulf I, et al. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. J Clin Sleep Med. 2023;19(10):1811-1822.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium OxybateIdiopathic HypersomniaDisorders of Excessive SomnolenceHumansAdultFemaleMaleSleepDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

quality of lifesleep inertiasleepinesswork productivity

Substanzen

Sodium Oxybate

Autor:innen und Institutionen

  • Janet Weis Children's Hospital, Geisinger, Danville, Pennsylvania.
  • Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.
  • University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France.
  • Sleep Disorder Unit, Pitié-Salpêtrière Hospital and Sorbonne University, Paris, France.
  • Albert Einstein College of Medicine, Bronx, New York.
  • Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Zitieren

APA

Morse, A. M., Dauvilliers, Y., Arnulf, I., Thorpy, M. J., Foldvary-Schaefer, N., Chandler, P., Chen, A., Hickey, L., Black, J., & Bogan, R. K. (2023). Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.10698

Vancouver

Morse AM, Dauvilliers Y, Arnulf I, Thorpy MJ, Foldvary-Schaefer N, Chandler P, et al. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. Journal of Clinical Sleep Medicine. 2023. doi:10.5664/jcsm.10698

BibTeX
@article{Morse2023,
  author = {Morse, Anne Marie and Dauvilliers, Yves and Arnulf, Isabelle and Thorpy, Michael J and Foldvary-Schaefer, Nancy and Chandler, Patricia and Chen, Abby and Hickey, Luke and Black, Jed and Bogan, Richard K},
  title = {Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia},
  journal = {Journal of Clinical Sleep Medicine},
  year = {2023},
  doi = {10.5664/jcsm.10698}
}
Kostenlos starten →